The Oscar Odyssey

The Oscar Odyssey

We all know that many health tech names have struggled since going public. Insurtechs have been no different, as an incredibly difficult industry to crack for a new entrant. Today we’re diving into Oscar’s beginnings, its rise to public company, and then its fall into the abyss. Then, we’ll be taking a look at Oscar’s transformation and atonement for past transgressions, what’s on the horizon for the insurtech, and why, despite past slip-ups, Oscar could be poised for a major comeback.

Read More

Home Health Bidding Wars

UnitedHealth Group is once again coming for a major home health player. After Option Health Care in early May announced its intention to merge with Amedisys in a deal valued around $10 billion (Amedisys comprising around $3.6B of the combined enterprise at the time), Optum announced an offer to acquire Amedisys outright in an all-cash deal at $100 / share.

Read More

Hippocratic AI: Hypocritical, or Not?

On May 16, a16z and General Catalyst announced their latest venture investment, pumping $50 million in seed money into a new upstart called Hippocratic AI. The media blitz on this one was so strong, you might’ve thought that the firm had succeeded in raising Hippocrates from the dead.

No – instead, Hippocratic AI will focus on building and enhancing a large-language model (LLM) specialized for healthcare to build AI applications. Similar.

Read More